Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival

• Автори: Hind A. Alkhatabi (Автор), Samir F. Zohny (Автор), Mohammed Razeeth Shait Mohammed (Автор), Hani Choudhry (Автор), Mohd Rehan (Автор), Aamir Ahmad (Автор), Farid Ahmed (Автор), Mohammad Imran Khan (Автор)
• Формат: Книга
• Опубліковано: MDPI AG, 2022-02-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid leukemia (AML) or elderly patients non-eligible for chemotherapy. However, acquiring resistance to ven...